Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony- stimulating factor

Transfusion

Volumn 52, Issue 8, 2012, Pages 1785-1791

  Varmavuo, Ville ^a,b,c   Mäntymaa, Pentti ^a,b,c   Kuittinen, Taru ^a,b,c   Nousiainen, Tapio ^a,b,c   Jantunen, Esa ^a,b,c  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b Laboratory of Eastern Finland   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CARBOPLATIN; CD16 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MESNA; MITOXANTRONE; PLERIXAFOR; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINBLASTINE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CRYOPRESERVATION; ENGRAFTMENT; FEMALE; HELPER CELL; HUMAN; LEUKAPHERESIS; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MALE; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; SUPPRESSOR CELL; T LYMPHOCYTE SUBPOPULATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD COMPONENT REMOVAL; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; HUMANS; LEUKOCYTE COUNT; LYMPHOCYTE SUBSETS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREDNISONE; RECEPTORS, CXCR4; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; VINCRISTINE;

EID: 84863836508     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2011.03525.x     Document Type: Article

References (24)

1. De Clercq E,. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol 2009; 77: 1655-64.
2. Hendrix CW, Flexner C, MacFarland RT, Giandomenico C, Fuchs EJ, Redpath E, Bridger G, Henson GW,. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000; 44: 1667-73.
3. Liles WC, Broxmeyer HE, Rodger E, Wood B, Hübel K, Cooper S, Hangoc G, Bridger GJ, Henson GW, Calandra G, Dale DC,. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003; 102: 2728-30.
4. Hübel K, Liles WC, Broxmeyer HE, Rodger E, Wood B, Cooper S, Hangoc G, Macfarland R, Bridger GJ, Henson GW, Calandra G, Dale DC,. Leukocytosis and mobilization of CD34+ hematopoietic progenitor cells by AMD3100, a CXCR4 antagonist. Support Cancer Ther 2004; 1: 165-72.
5. Devine SM, Flomenberg N, Vesole DH, Liesveld J, Weisdorf D, Badel K, Calandra G, DiPersio JF,. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 1095-102.
6. Flomenberg N, Devine SM, DiPersio JF, Liesveld JL, McCarty JM, Rowley SD, Vesole DH, Badel K, Calandra G,. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867-74.
7. Dugan MJ, Maziarz RT, Bensinger WI, Nademanee A, Liesveld J, Badel K, Dehner C, Gibney C, Bridger G, Calandra G,. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 2010; 45: 39-47.
8. Jantunen E, Fruehauf S,. Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens. Bone Marrow Transplant 2011; 46: 627-35.
9. Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, West W,. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-9.
10. Allan DS, Keeney M, Howson-Jan K, Popma J, Weir K, Bhatia M, Sutherland DR, Chin-Yee IH,. Number of viable CD34(+) cells re-infused predict engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 967-72.
11. Liles WC, Rodger E, Broxmeyer HE, Dehner C, Badel K, Calandra G, Christensen J, Wood B, Price TH, Dale DC,. Augmented mobilization and collection of CD34+ hematopoietic cells from normal volunteers stimulated with granulocyte-colony-stimulating factor by a single-dose of AMD3100, a CXCR4 antagonist. Transfusion 2005; 45: 295-300.
12. Gazitt Y, Freytes CO, Akay C, Badel K, Calandra G,. Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulation factor in non-Hodgkin's lymphoma patiens. Stem Cells Dev 2007; 16: 657-66.
13. Gazitt Y, Shaughnessy P, Devore P,. Mobilization of dendritic cells and NK cell in non-Hodgkin's lymphoma patients mobilized with different growth factors. J Hematother Stem Cell Res 2001; 10: 117-86.
14. Porrata LF, Litzow MR, Inwards DJ, Gastineau DA, Moore SB, Pineda AA, Bundy KL, Padley DJ, Persky D, Ansell SM, Micallef IN, Markovic SN,. Infused peripheral blood autograft lymphocyte count correlated with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 291-8.
15. Holtan SG, Porrata LF, Micallef IN, Padley DJ, Inwards DJ, Ansell SA, Johnston PB, Gastineau DA, Markovic SN,. AMD3100 affects autograft lymphocyte collection and progression-free survival in non-Hodgkin lymphoma. Clin Lymphoma Myeloma 2007; 7: 315-8.
16. Takahaski Y, Chakrabarti S, Sriniivasan R, Lundqvist A, Read EJ, Khuu H, Leitman S, Bolan C, Barrett AJ, Calandra G, Childs R,. A detailed phenotypic analysis using six color flow cytometry of lymphocyte subsets mobilized with AMD3100 compared to G-CSF [abstract]. Blood 2004; 104: 120a #408.
17. Gaugler B, Arbez J, Frikeche J, Le Gouill S, Gastinne T, Blin N, Chevallier P, Guillaume T, Delaunay J, Ayari S, Rialland F, Mahe B, Dubruille V, Clavert A, Rolland V, Saas P, Moreau P, Derenne S, Mohty M,. Characterization of peripheral blood stem cell grafts mobilized by G-CSF and plerixafor in comparison to G-CSF alone [abstract]. Bone Marrow Transplant 2011; 46 Suppl 1: S61 #380.
18. Jantunen E, Kuittinen T, Mahlamäki E, Pyörälä M, Mäntymaa P, Nousiainen T,. Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience. Eur J Haematol 2011; 86: 299-304.
19. Jantunen E, Lemoli RM,. Preemptive use of plerixafor in difficult-to mobilize patients: an emerging concept. Transfusion 2012; 52: 906-14.
20. Porrata LF, Gastineau DA, Padley D, Bundy K, Markovic SN,. Re-infused autologous graft natural killer cells correlates with absolute lymphocyte count recovery after autologous stem cell transplantation. Leuk Lymphoma 2003; 44: 997-1000.
21. Atta EH, de Azevedo AM, Maiolino A, Coelho CJ, Sarcinelli SM, de Alvarenga Máximo C, Marra VL,. High CD8+ lymphocyte dose in the autograft predicts early absolute lymphocyte count recovery after peripheral hematopoietic stem cell transplantation. Am J Hematol 2009; 84: 21-8.
22. DiPersio JF, Ho AD, Hanrahan J, Hsu FJ, Fruehauf S,. Relevance and clinical implications of tumor cell mobilization in the autologous transplant setting. Biol Blood Marrow Transplant 2011; 17: 943-55.
23. Fruehauf S, Ehninger G, Hübel K, Topaly J, Goldschmidt H, Ho AD, Müller S, Moos M, Badel K, Calandra G,. Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients. Bone Marrow Transplant 2010; 45: 269-75.
24. Morris C, Sureda A, van Biezen A, Mohty M, Ljungman P, Iacobelli S, Boumendil A, Basak GW, de Witte T, Dreger P,. The EMA-directed plerixafor safety survey: the EBMT CALM study [abstract]. Bone Marrow Transplant 2011; 46 Suppl 1: S32 #244.